News | January 06, 2022
Margins under pressure; domestic market growth to slow down: Nirmal Bang
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
It is the generic version of molnupiravir
Biogen paid Ionis a US $ 60 million one-time upfront payment
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Partnering to build biosynthesis processes and a pharmaceutical production platform
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Subscribe To Our Newsletter & Stay Updated
